$12.81
-0.13 (-1.00%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-82.24%
1Y
-57.11%
YTD
-82.23%
Open$12.89
Previous Close$12.94
Day High$13.14
Day Low$12.76
52W High$73.06
52W Low$11.40
Volume—
Avg Volume201.3K
Market Cap216.56M
P/E Ratio—
EPS$-3.86
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$72.38
Below
SMA 200
$51.57
Below
RSI (14)
65.9
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
5 analysts
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 18.61M | 11.75M | 2.36B |
| Net Income | -49,476,359 | -28,104,470 | -651,372,475 |
| Profit Margin | -265.9% | -252.6% | -27.6% |
| EBITDA | -49,283,065 | -29,549,931 | -865,943,607 |
| Free Cash Flow | — | — | -400,975,764 |
| Rev Growth | +58.4% | +58.4% | +6.9% |
| Debt/Equity | — | — | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |